Sionna Therapeutics, Inc. (SION) — Stock Score Summary

Sionna Therapeutics, Inc. (SION) has a MoatMap StockRank of 33/100 based on Quality (42/100), Value (36/100), and Momentum (42/100) factor scores. The current signal is SELL. Sionna Therapeutics is a clinical-stage biotech company focusing on cystic fibrosis. It lacks commercialized products, positive cash flows, and does not fit our quality compounder or macro theme criteria.

Sionna Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing novel small molecule therapeutics for cystic fibrosis (CF), aiming to restore function to the critical CFTR protein. Its competitive moat lies in an innovative scientific approach that targets distinct mechanisms to restore CFTR function, potentially offering superior benefits or reaching patient populations underserved by current therapies. Sionna is focused on delivering best-in-class or first-in-class treatments for this specific genetic disorder.

Key Financial Metrics

Price$33.69
Market Cap$1.9B
P/E (Forward)-13.48
Price/Book5.91
Return on Equity-26.7%
Return on Invested Capital-28.3%
Debt/Equity2.91
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-46M

Sionna Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Sionna Therapeutics, Inc.’s (SION) StockRank?
MoatMap’s StockRank for Sionna Therapeutics, Inc. (SION) is 33/100, with a Sell signal. It is a composite of Quality (42), Value (36), and Momentum (42) factor ranks across MoatMap’s 19,000+ stock universe.
Does Sionna Therapeutics, Inc. have an economic moat?
Sionna Therapeutics, Inc. (SION) has a Quality factor score of 42/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Sionna Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Sionna Therapeutics, Inc. (SION) is Sell, based on a StockRank of 33/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Sionna Therapeutics, Inc. in?
Sionna Therapeutics, Inc. (SION) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksSION deep dive reportAI ChampionsHow we score stocksSense-check another stock